Hoffmann-la Roche

This study tests whether a higher dose of the drug ocrelizumab can better slow disability progression in people with primary progressive multiple sclerosis (PPMS). About 769 adults with PPMS will receive either the standard dose or a higher dose every 24 weeks. The main goal is t…

This study tests whether a combination of two drugs (atezolizumab and bevacizumab) can delay or prevent liver cancer from returning in patients who have had surgery or ablation to remove their tumors. About 668 adults with liver cancer at high risk of recurrence will be randomly …

This study tests a drug called satralizumab in 127 people with moderate-to-severe thyroid eye disease, a condition that causes eye bulging, pain, and double vision. The drug aims to reduce eye bulging by at least 2 millimeters over 24 weeks. Participants receive injections or a p…

This phase 3 study compares an experimental daily pill, fenebrutinib, with an approved drug, teriflunomide, in about 750 adults with relapsing multiple sclerosis. The goal is to see if fenebrutinib can better reduce relapse rates and delay worsening disability. Participants are r…

This study tests whether adding an experimental drug (RO7204239) that helps muscles grow to an existing SMA treatment (risdiplam) can improve motor function more than risdiplam alone. About 259 people with SMA, aged 2 to 25 years, will take part. The trial first finds the best do…

This study tests whether adding a new drug (giredestrant) to standard therapy (Phesgo) can help people with a certain type of advanced breast cancer (HER2-positive and ER-positive) live longer without their cancer growing. About 922 participants will receive either the combinatio…

This study tests a new treatment called OpRegen for people with advanced dry age-related macular degeneration (geographic atrophy), a leading cause of vision loss. The treatment uses special cells grown from stem cells that are placed under the retina to replace damaged cells. Th…

This study tests a new once-daily drug, RO7795081, for helping people with obesity or overweight who also have weight-related health problems like high blood pressure or sleep apnea. About 340 adults will take either the drug or a placebo for 38 weeks to see how much weight they …

This study tested the drug ocrelizumab in 927 adults with progressive multiple sclerosis (MS) to see if it can slow down worsening of the disease. Participants received the drug for up to 4 years, and researchers measured how many had no signs of disability getting worse. The goa…

This study tests a new immunotherapy drug called tobemstomig combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer that has not been treated before. The goal is to see if this combination works better than the current standard treatmen…

This study tests several targeted therapies for people with advanced or metastatic non-small cell lung cancer. A simple blood test identifies specific genetic changes in the tumor, allowing doctors to match each patient with a drug that may work better for their cancer. The goal …

This study tests whether adding tiragolumab to standard treatment (atezolizumab plus chemotherapy) helps people with untreated extensive-stage small cell lung cancer live longer without their cancer growing. About 123 participants in China will receive either the new combination …

This study tests a drug called entrectinib in people with advanced solid tumors that have certain gene changes (NTRK, ROS1, or ALK). The drug aims to shrink or control the cancer by blocking these faulty genes. About 534 adults with various cancers, including lung, breast, and br…

This study tests an experimental drug called entrectinib in children and teens with advanced solid tumors or brain cancers that have come back or not responded to other treatments. The goal is to find the safest dose and see if the drug can shrink tumors, especially in those with…

This study is testing several new drugs that are chosen based on the specific genetic markers found in a person's rare ovarian tumor. It includes 176 adults whose ovarian, fallopian tube, or peritoneal cancer has come back or not gone away after standard treatment. The goal is to…

This study tests a new medicine, crovalimab, in healthy volunteers and people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease that destroys red blood cells. The goal is to see if the drug is safe and can control the disease by blocking part of the immune syst…

This study offers ongoing treatment with alectinib or crizotinib to people with ALK- or RET-positive cancer who were already benefiting from these drugs in a previous Roche trial. The goal is to keep providing the medication safely while monitoring side effects and survival. Abou…

This study tests an experimental antibody drug called prasinezumab in people with early Parkinson's disease. The goal is to see if it can slow down worsening of symptoms over 52 weeks compared to a placebo. The trial involves 316 participants and includes a long-term extension to…

This study tests a medicine called faricimab, given as an eye injection, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if injections given every 24 weeks can safely maintain or improve vision. About 274 participant…

This study aimed to test if crovalimab, added to standard blood thinners, could prevent dangerous blood clots in adults with antiphospholipid syndrome (APS), an autoimmune condition that raises clot risk. The trial was withdrawn before enrolling any participants, so no results ar…

This study tests an experimental drug called RO7204239 in 51 adults with facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes progressive muscle weakness. The drug is designed to block a protein that limits muscle growth, aiming to slow muscle loss. Part…

This study tests an experimental drug called fenebrutinib in people with relapsing multiple sclerosis (RMS). The goal is to see if it can reduce new brain lesions seen on MRI scans compared to a placebo. About 109 participants will take either the drug or a placebo for 12 weeks, …

This study allows cancer patients who were already benefiting from atezolizumab in a previous Roche-sponsored trial to keep receiving the drug if they have no other local options. It includes 49 participants and focuses on safety and continued treatment access. The goal is to ens…

This study follows 1,200 people in China who have just been diagnosed with advanced non-small-cell lung cancer (stage IIIB, IIIC, or IV) that cannot be removed by surgery. Researchers will collect information from medical records and follow participants over time to see what trea…